Analysts Conflictied on These Healthcare Names: Amedisys (NASDAQ: AMED) and Merus NV (NASDAQ: MRUS)

By Jason Carr

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Amedisys (NASDAQ: AMED) and Merus NV (NASDAQ: MRUS).

Amedisys (NASDAQ: AMED)

In a report released today, Sheryl Skolnick from Mizuho Securities upgraded Amedisys (NASDAQ: AMED) to Buy. The company’s shares closed last Friday at $38.20.

According to TipRanks.com, Skolnick is a 3-star analyst with an average return of 2.3% and a 60.0% success rate. Skolnick covers the Healthcare sector, focusing on stocks such as Kindred Healthcare, Community Health, and LifePoint Health.

Currently, the analyst consensus on Amedisys is Strong Buy and the average price target is $56, representing a 46.6% upside.

In a report issued on October 31, Jefferies also reiterated a Buy rating on the stock with a $50 price target.
Merus NV (NASDAQ: MRUS)

Merus NV (NASDAQ: MRUS) received a Hold rating and a $19 price target from Citigroup analyst Yigal Nochomovitz today. The company’s shares closed last Friday at $15.21.

According to TipRanks.com, Nochomovitz is ranked 0 out of 5 stars with an average return of -9.4% and a 35.1% success rate. Nochomovitz covers the Healthcare sector, focusing on stocks such as Merrimack Pharmaceuticals, Anthera Pharmaceuticals, and Lexicon Pharmaceuticals.

Merus NV has an analyst consensus of Moderate Buy.